News

2017 Feb 09

Collaboration Employs New Strategies to Study the Spread of Cancer

Video of If cancer didn’t metastasize, or spread, it would be easy to cure, says Dr. Lewis Cantley , the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “We could merely cut it out, and... Read more

2017 Feb 09

Collaboration employs new strategies to study the spread of cancer

Feature about the new Center on the Physics of Cancer Metabolism collaboration between Ithaca and NYC. Read more

2017 Feb 09

Weill Cornell Medicine scientists seek to improve ovarian cancer therapies

Juan Cubillos-Ruiz and colleagues have been awarded a grant to define the role of a potentially crucial biomarker in the treatment of ovarian cancer tumors. Read more

2017 Feb 08

Medical Marvels: Life-saving treatment for chronic leukemia

Richard Furman, M.D. and patient Robert Frank Azopardi were recently featured on the abc7NY Medical Marvels series. Read more

2017 Feb 06

Old drug may provide new hope to melanoma patients

Diabetes drug phenformin shows promise as a treatment for melanoma, according to research from Lewis Cantley, Ph.D., and Jonathan Zippin, M.D., Ph.D. Read more

2017 Feb 02

Expert discusses upcoming agents to treat follicular lymphoma

John Leonard, M.D. discusses advancements in the treatment of follicular lymphoma. Read more

2017 Feb 01

Artificial Intelligence helps identify effective cancer drug combinations

Artificial intelligence (AI) can help scientists predict what combinations of already existing drugs may work in different types of cancer, according to two new studies from the lab of Olivier Elemento, Ph.D. Read more

2017 Jan 31

Grad student honored for teaching, cancer patient program

Peter DelNero, a doctoral candidate in biomedical engineering who works in the lab of Cornell University associate Claudia Fischbach-Teschl, Ph.D, has received the 2017 K. Patricia Cross Future Leaders Award. DelNero is one of eight graduate students nationwide to receive this prestigious award out of more than 250 nominees from 127 institutions. Read more

2017 Jan 30

Martin discusses ibrutinib-palbociclib combo in mantle cell lymphoma

Peter Martin, M.D., discusses the results of a trial testing the combination of ibrutinib and palbociclib for patients being treated for mantle cell lymphoma. Read more

2017 Jan 27

Jaffrey wins Abel Award

Dr. Samie Jaffrey, the Greenberg-Starr Professor and a professor of pharmacology at Weill Cornell Medicine, has received the 2017 John J. Abel Award in Pharmacology from the American Society for Pharmacology and Experimental Therapeutics. Read more

2017 Jan 27

Cantley elected as board chair of Hope Funds

Meyer director Lewis Cantley, Ph.D., was recently elected as Chairman of the Board of Trustees of the Hope Funds for Cancer Research, a charity dedicated to advancing innovative research for the most difficult-to-treat cancers. Read more

2017 Jan 27

Stopping gliomas in their tracks

Drugs currently used to treat myeloproliferative disorders may help halt brain cancer before it becomes incurable. Read more

Moonsoo Jin, Ph.D., has developed a way to track CAR-T cells in the body using a radiotracer

2017 Jan 27

GPS for CAR-T

Moonsoo M. Jin, Ph.D., and colleagues at the Molecular Imaging Innovations Institute, have developed a method to map infused T cells throughout the body, which could improve the safety and efficacy of immunotherapy. Read more

2017 Jan 25

We Are Weill Cornell Medicine: Dr. Heather Yeo

Heather Yeo, M.D., is a featured faculty member in the #WeAreWCM campaign. Read more

2017 Jan 25

A prostate cancer that sidesteps therapy

Feature about the work of Himisha Beltran, M.D., to uncover the evolution of aggressive forms of prostate cancer. Read more

2017 Jan 18

Cantley named as NCI Outstanding Investigator

Meyer director Lewis Cantley will receive $4.2 million over 7 years to continue his research into PI3K and cancer metabolism. Read more

2017 Jan 17

Ofatumumab improves overall response in Waldenström macroglobulinemia

A study by Richard Furman, M.D., found that ofatumumab may be a non-chemotherapeutic option for patients with Waldenström macroglobulinemia. Read more

Innovation from Weill Cornell Medicine scientists + the best medical care from NewYork-Presbyterian doctors puts Meyer Cancer Center first in NYC cancer care.

2017 Jan 17

My visit to the medical Holodeck

Feature about the use of virtual reality for cancer research at Weill Cornell Medicine. Read more

2017 Jan 13

Anti-science culture is growing, say Nobel Laureates

Harold Varmus, M.D., warned against the "anti-science movement" during a visit to India for the Nobel Prize Series. Read more

2017 Jan 12

Exploring epigenetic therapy for aggressive prostate cancer

With the help of a 2016 Lori Milken–PCF Young Investigator Award from the Prostate Cancer Foundation, Loredana Puca, Ph.D., is studying the genomic characteristics of neuroendocrine prostate cancer and whether it might be possible to develop an epigenetic therapy to treat it. Read more

News

Collaboration Employs New Strategies to Study the Spread of Cancer

Collaboration employs new strategies to study the spread of cancer

Weill Cornell Medicine scientists seek to improve ovarian cancer therapies

Medical Marvels: Life-saving treatment for chronic leukemia

Old drug may provide new hope to melanoma patients

Expert discusses upcoming agents to treat follicular lymphoma

Artificial Intelligence helps identify effective cancer drug combinations

Grad student honored for teaching, cancer patient program

Martin discusses ibrutinib-palbociclib combo in mantle cell lymphoma

Jaffrey wins Abel Award

Cantley elected as board chair of Hope Funds

Stopping gliomas in their tracks

GPS for CAR-T

We Are Weill Cornell Medicine: Dr. Heather Yeo

A prostate cancer that sidesteps therapy

Cantley named as NCI Outstanding Investigator

Ofatumumab improves overall response in Waldenström macroglobulinemia

My visit to the medical Holodeck

Anti-science culture is growing, say Nobel Laureates

Exploring epigenetic therapy for aggressive prostate cancer

Follow us on X

2022 Annual Report

2021 Annual Report

2018 Annual Report

2017 Annual Report

2016 Annual Report

Newsletters